Home / Business and Economy / Zimmer Biomet Surpasses Profit Estimates Amid Device Demand
Zimmer Biomet Surpasses Profit Estimates Amid Device Demand
10 Feb
Summary
- Zimmer Biomet exceeded profit and revenue expectations for Q4.
- Net sales increased by 10.9% to $2.24 billion in the fourth quarter.
- Company anticipates 2026 earnings per share between $8.30 and $8.45.
Zimmer Biomet reported exceeding fourth-quarter financial expectations, with net sales climbing 10.9% to $2.24 billion. This performance was bolstered by consistent demand for the company's orthopedic devices, particularly in its hips and knees segments, which experienced sales increases of 7.9% and 6%, respectively.
The orthopedic device maker's positive financial results reflect a broader trend of increased demand in the medical device industry, as patients schedule more procedures. Zimmer Biomet's CEO noted that a strategic shift to a more specialized U.S. sales model is expected to impact 2026 sales growth but should support long-term expansion.
Looking ahead, Zimmer Biomet anticipates 2026 earnings per share to be between $8.30 and $8.45. The company also forecasts revenue growth of 2.5% to 4.5% for the current year, with an anticipated foreign currency impact of 0.5%.
